Immuno-oncologyNew ITGA2-targeting ADCs reported in Inxmed patentInxmed (Nanjing) Co. Ltd. has divulged antibody-drug conjugates comprising an antibody targeting integrin α-2 β1 (ITGA2; CD49b; VLA-2) covalently linked to a cytotoxic drug reported to be useful for the treatment of cancer.